Daniel Bazarko Form 3 ALEXION PHARMACEUTICALS / Daniel Bazarko ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Bazarko Daniel

(Last)

(First)

(Middle)

C/O ALEXION PHARMACEUTICALS, INC.

121 SEAPORT BOULEVARD

(Street)

BOSTON

02210

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
02/19/2019

3. Issuer Name and Ticker or Trading Symbol
ALEXION PHARMACEUTICALS, INC. [ ALXN ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
SVP, Controller, CAO

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock, par value $.0001 per share	243⁽¹⁾	D
Common Stock, par value $.0001 per share	1,350⁽²⁾	D
Common Stock, par value $.0001 per share	219⁽³⁾	D
Common Stock, par value $.0001 per share	4,762⁽⁴⁾	D
Common Stock, par value $.0001 per share	2,294⁽⁵⁾	D
Common Stock, par value $.0001 per share	2,025⁽⁶⁾	D
Common Stock, par value $.0001 per share	5,020	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Option to Purchase Common Stock	⁽⁷⁾	02/27/2025	Common Stock, par value $.0001 per share	3,943	180.37	D
Option to Purchase Common Stock	⁽⁸⁾	12/01/2025	Common Stock, par value $.0001 per share	2,912	180.28	D
Option to Purchase Common Stock	⁽⁹⁾	06/01/2023	Common Stock, par value $.0001 per share	13,066	97.58	D
Option to Purchase Common Stock	⁽¹⁰⁾	02/28/2024	Common Stock, par value $.0001 per share	5,111	176.8	D
Option to Purchase Common Stock	⁽¹¹⁾	02/28/2027	Common Stock, par value $.0001 per share	5,300	131.25	D
Option to Purchase Common Stock	⁽¹²⁾	02/28/2026	Common Stock, par value $.0001 per share	11,000	140.16	D

Explanation of Responses:

1. Award of Restricted Stock Unites under the 2004 Incentive Plan. 25% of the shares vest on each anniversary of the grant date. The grant date of this award was December 1, 2015. The number of shares reported are the remaining unvested shares.

2. Award of Restricted Stock Unites under the 2004 Incentive Plan. 25% of the shares vest on each anniversary of the grant date. The grant date of this award was February 26, 2016. The number of shares reported are the remaining unvested shares.

3. Award of Restricted Stock Unites under the 2004 Incentive Plan. 25% of the shares vest on each anniversary of the grant date. The grant date of this award was February 27, 2015. The number of shares reported are the remaining unvested shares.

4. Award of Restricted Stock Unites under the 2017 Incentive Plan. 25% of the shares vest on each anniversary of the grant date. The grant date of this award was February 28, 2018. The number of shares reported are the remaining unvested shares.

5. Award of Restricted Stock Unites under the 2017 Incentive Plan. 50% of the shares vest on each of the first two anniversaries of the grant date. The grant date of this award was December 1, 2017. The number of shares reported are the remaining unvested shares.

6. Award of Restricted Stock Unites under the 2004 Incentive Plan. 25% of the shares vest on each anniversary of the grant date. The grant date of this award was February 28, 2017. The number of shares reported are the remaining unvested shares.

7. Award of stock options under the 2004 Incentive Plan. 25% vest on the one year anniversary of the date of the grant and 1/16th every 90 days thereafter. The grant date for this award was February 27, 2015.

8. Award of stock options under the 2004 Incentive Plan. 25% vest on the one year anniversary of the date of the grant and 1/16th every 90 days thereafter. The grant date for this award was December 1, 2015.

9. Award of stock options under the 2004 Incentive Plan. 25% vest on the one year anniversary of the date of the grant and 1/16th every 90 days thereafter. The grant date for this award was June 1, 2013.

10. Award of stock options under the 2004 Incentive Plan. 25% vest on the one year anniversary of the date of the grant and 1/16th every 90 days thereafter. The grant date for this award was February 28, 2014.

11. Award of stock options under the 2004 Incentive Plan. 25% vest on the one year anniversary of the date of the grant and 1/16th every 90 days thereafter. The grant date for this award was February 28, 2017

12. Award of stock options under the 2004 Incentive Plan. 25% vest on the one year anniversary of the date of the grant and 1/16th every 90 days thereafter. The grant date for this award was February 26, 2016.

Remarks:

	/s/ Douglas Barry, Attorney-in-Fact for Daniel Bazarko	02/19/2019
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Daniel Bazarko Form 3ALEXION PHARMACEUTICALS / Daniel Bazarko ownership change